PET with fluorodeoxyglucose F 18/computed tomography in the clinical management and patient outcomes of esophageal cancer

Robert M. Kwee; Charles Marcus; Sara Sheikhbahaei; Rathan M Subramaniam

doi:10.1016/j.cpet.2014.12.003

PET with fluorodeoxyglucose F 18/computed tomography in the clinical management and patient outcomes of esophageal cancer

Robert M. Kwee, Charles Marcus, Sara Sheikhbahaei, Rathan M Subramaniam

School of Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

PET with fluorodeoxyglucose F 18/computed tomography (¹⁸F-FDG PET/CT) has evolved into an indispensable imaging technique in the management of patients with esophageal cancer. Staging with ¹⁸F-FDG PET/CT is strongly associated with overall survival and certain ¹⁸F-FDG PET/CT parameters predict patient survival. Current evidence supporting the validity of the use of ¹⁸F-FDG PET/CT in the tumor delineation process for radiation treatment planning in patients with esophageal cancer is still limited. It is useful in determining treatment response after neoadjuvant therapy and thereby has an impact on management. ¹⁸F-FDG PET/CT plays a role in the diagnosis of recurrent disease in patients with a background of clinical suspicion.

Original language	English (US)
Pages (from-to)	197-205
Number of pages	9
Journal	PET Clinics
Volume	10
Issue number	2
DOIs	https://doi.org/10.1016/j.cpet.2014.12.003
State	Published - Apr 1 2015

Keywords

Computed tomography
Esophageal cancer
F-Fluorodeoxyglucose
Management
Positron emission tomography

ASJC Scopus subject areas

Radiation
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.cpet.2014.12.003

Cite this

@article{0b60f9bec172465794380340555729f6,

title = "PET with fluorodeoxyglucose F 18/computed tomography in the clinical management and patient outcomes of esophageal cancer",

abstract = "PET with fluorodeoxyglucose F 18/computed tomography (18F-FDG PET/CT) has evolved into an indispensable imaging technique in the management of patients with esophageal cancer. Staging with 18F-FDG PET/CT is strongly associated with overall survival and certain 18F-FDG PET/CT parameters predict patient survival. Current evidence supporting the validity of the use of 18F-FDG PET/CT in the tumor delineation process for radiation treatment planning in patients with esophageal cancer is still limited. It is useful in determining treatment response after neoadjuvant therapy and thereby has an impact on management. 18F-FDG PET/CT plays a role in the diagnosis of recurrent disease in patients with a background of clinical suspicion.",

keywords = "Computed tomography, Esophageal cancer, F-Fluorodeoxyglucose, Management, Positron emission tomography",

author = "Kwee, {Robert M.} and Charles Marcus and Sara Sheikhbahaei and Subramaniam, {Rathan M}",

year = "2015",

month = apr,

day = "1",

doi = "10.1016/j.cpet.2014.12.003",

language = "English (US)",

volume = "10",

pages = "197--205",

journal = "PET Clinics",

issn = "1556-8598",

publisher = "W.B. Saunders Ltd",

number = "2",

}

TY - JOUR

T1 - PET with fluorodeoxyglucose F 18/computed tomography in the clinical management and patient outcomes of esophageal cancer

AU - Kwee, Robert M.

AU - Marcus, Charles

AU - Sheikhbahaei, Sara

AU - Subramaniam, Rathan M

PY - 2015/4/1

Y1 - 2015/4/1

N2 - PET with fluorodeoxyglucose F 18/computed tomography (18F-FDG PET/CT) has evolved into an indispensable imaging technique in the management of patients with esophageal cancer. Staging with 18F-FDG PET/CT is strongly associated with overall survival and certain 18F-FDG PET/CT parameters predict patient survival. Current evidence supporting the validity of the use of 18F-FDG PET/CT in the tumor delineation process for radiation treatment planning in patients with esophageal cancer is still limited. It is useful in determining treatment response after neoadjuvant therapy and thereby has an impact on management. 18F-FDG PET/CT plays a role in the diagnosis of recurrent disease in patients with a background of clinical suspicion.

AB - PET with fluorodeoxyglucose F 18/computed tomography (18F-FDG PET/CT) has evolved into an indispensable imaging technique in the management of patients with esophageal cancer. Staging with 18F-FDG PET/CT is strongly associated with overall survival and certain 18F-FDG PET/CT parameters predict patient survival. Current evidence supporting the validity of the use of 18F-FDG PET/CT in the tumor delineation process for radiation treatment planning in patients with esophageal cancer is still limited. It is useful in determining treatment response after neoadjuvant therapy and thereby has an impact on management. 18F-FDG PET/CT plays a role in the diagnosis of recurrent disease in patients with a background of clinical suspicion.

KW - Computed tomography

KW - Esophageal cancer

KW - F-Fluorodeoxyglucose

KW - Management

KW - Positron emission tomography

UR - http://www.scopus.com/inward/record.url?scp=84926143838&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926143838&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2014.12.003

DO - 10.1016/j.cpet.2014.12.003

M3 - Review article

C2 - 25829086

AN - SCOPUS:84926143838

SN - 1556-8598

VL - 10

SP - 197

EP - 205

JO - PET Clinics

JF - PET Clinics

IS - 2

ER -

PET with fluorodeoxyglucose F 18/computed tomography in the clinical management and patient outcomes of esophageal cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this